Symbols / GOSS Stock $0.22 +8.14% Gossamer Bio, Inc.
GOSS (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-19 | main | Barclays | Underweight → Underweight | $0 |
| 2026-03-23 | down | Cantor Fitzgerald | Overweight → Neutral | — |
| 2026-03-06 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2026-03-05 | main | Oppenheimer | Outperform → Outperform | $3 |
| 2026-02-24 | down | Wedbush | Outperform → Neutral | $1 |
| 2026-02-24 | down | Barclays | Overweight → Underweight | $0 |
| 2026-02-24 | down | Leerink Partners | Outperform → Market Perform | $1 |
| 2026-01-28 | init | Barclays | — → Overweight | $9 |
| 2026-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-09-11 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-09-10 | up | UBS | Neutral → Buy | $9 |
| 2025-08-06 | main | Wedbush | Outperform → Outperform | $5 |
| 2025-07-14 | init | Scotiabank | — → Sector Outperform | $11 |
| 2025-05-16 | main | Goldman Sachs | Buy → Buy | $8 |
| 2025-05-16 | reit | Wedbush | Outperform → Outperform | $4 |
| 2025-04-17 | main | Goldman Sachs | Buy → Buy | $7 |
| 2025-03-14 | reit | Wedbush | Outperform → Outperform | $4 |
| 2025-01-30 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-09-17 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
- symbol__ Stock Quote Price and Forecast - CNN Wed, 20 May 2026 01
- GOSS Technical Analysis | Trend, Signals & Chart Patterns | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill Mon, 18 May 2026 07
- GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Clinical Execution Failures: Levi & Korsinsky - PR Newswire Wed, 20 May 2026 13
- Goldman Sachs Adjusts Outlook for Gossamer Bio (GOSS) - GuruFocus Wed, 20 May 2026 20
- GOSS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan Fri, 15 May 2026 22
- Robbins LLP Reminds GOSS Investors of the Pending Class - GlobeNewswire Wed, 20 May 2026 20
- Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS) - Yahoo Finance Mon, 18 May 2026 14
- GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - PR Newswire Mon, 18 May 2026 16
- Gossamer Bio moves to swap $200M in notes for stock, new debt - Stock Titan Mon, 18 May 2026 11
- Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who - GlobeNewswire Mon, 18 May 2026 17
- Pulmonary hypertension drug developer Gossamer Bio sets May 18 Q1 update - Stock Titan Fri, 15 May 2026 11
- PAH inhaler FDA filing planned as Gossamer targets $128M debt swap - Stock Titan Mon, 18 May 2026 11
- Debt exchange and FDA path shape Gossamer Bio (NASDAQ: GOSS) - Stock Titan Mon, 18 May 2026 11
- GOSS Maintained by Barclays -- Price Target Lowered to $0.28 - GuruFocus ue, 19 May 2026 13
- Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance Fri, 15 May 2026 23
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
48.47
-57.74%
|
114.70
|
0.00
|
0.00
|
| Operating Revenue |
|
48.47
-57.74%
|
114.70
|
0.00
|
0.00
|
| Operating Expense |
|
211.72
+21.25%
|
174.62
+0.50%
|
173.76
-20.49%
|
218.53
|
| Research And Development |
|
174.09
+25.71%
|
138.49
+2.35%
|
135.30
-20.84%
|
170.92
|
| Selling General And Administration |
|
37.63
+4.15%
|
36.13
-6.04%
|
38.45
-19.23%
|
47.61
|
| General And Administrative Expense |
|
37.63
+4.15%
|
36.13
-6.04%
|
38.45
-19.23%
|
47.61
|
| Other Gand A |
|
37.63
+4.15%
|
36.13
-6.04%
|
38.45
-19.23%
|
47.61
|
| Total Expenses |
|
211.72
+21.25%
|
174.62
+0.50%
|
173.76
-20.49%
|
218.53
|
| Operating Income |
|
-163.25
-172.46%
|
-59.92
+65.52%
|
-173.76
+20.49%
|
-218.53
|
| Total Operating Income As Reported |
|
-170.73
-184.93%
|
-59.92
+67.39%
|
-183.76
+15.94%
|
-218.59
|
| EBITDA |
|
-158.47
-296.49%
|
-39.97
+75.32%
|
-161.92
+23.29%
|
-211.07
|
| Normalized EBITDA |
|
-150.99
-277.79%
|
-39.97
+73.69%
|
-151.92
+28.00%
|
-211.00
|
| Reconciled Depreciation |
|
1.00
-75.86%
|
4.15
-5.34%
|
4.38
-0.99%
|
4.43
|
| EBIT |
|
-159.47
-261.46%
|
-44.12
+73.47%
|
-166.31
+22.83%
|
-215.50
|
| Total Unusual Items |
|
-7.47
|
0.00
+100.00%
|
-10.00
-15284.62%
|
-0.07
|
| Total Unusual Items Excluding Goodwill |
|
-7.47
|
0.00
+100.00%
|
-10.00
-15284.62%
|
-0.07
|
| Special Income Charges |
|
-7.47
|
0.00
+100.00%
|
-10.00
-15284.62%
|
-0.07
|
| Other Special Charges |
|
7.47
|
—
|
10.00
+15284.62%
|
0.07
|
| Net Income |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Pretax Income |
|
-170.46
-206.39%
|
-55.63
+69.06%
|
-179.82
+21.61%
|
-229.38
|
| Net Non Operating Interest Income Expense |
|
-9.02
+7.38%
|
-9.74
+15.42%
|
-11.51
+6.37%
|
-12.30
|
| Interest Expense Non Operating |
|
10.99
-4.58%
|
11.52
-14.76%
|
13.51
-2.66%
|
13.88
|
| Net Interest Income |
|
-9.02
+7.38%
|
-9.74
+15.42%
|
-11.51
+6.37%
|
-12.30
|
| Interest Expense |
|
10.99
-4.58%
|
11.52
-14.76%
|
13.51
-2.66%
|
13.88
|
| Interest Income Non Operating |
|
1.97
+10.74%
|
1.78
-10.92%
|
2.00
+26.15%
|
1.58
|
| Interest Income |
|
1.97
+10.74%
|
1.78
-10.92%
|
2.00
+26.15%
|
1.58
|
| Other Income Expense |
|
1.81
-87.06%
|
14.02
+157.00%
|
5.46
+277.06%
|
1.45
|
| Other Non Operating Income Expenses |
|
9.29
-33.75%
|
14.02
-9.28%
|
15.46
+922.22%
|
1.51
|
| Tax Provision |
|
-0.09
-109.85%
|
0.89
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Net Income From Continuing Operation Net Minority Interest |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Net Income From Continuing And Discontinued Operation |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Net Income Continuous Operations |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Normalized Income |
|
-162.90
-188.17%
|
-56.53
+66.71%
|
-169.82
+25.95%
|
-229.31
|
| Net Income Common Stockholders |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Diluted EPS |
|
-0.75
-200.00%
|
-0.25
+78.81%
|
-1.18
+56.46%
|
-2.71
|
| Basic EPS |
|
-0.75
-200.00%
|
-0.25
+78.81%
|
-1.18
+56.46%
|
-2.71
|
| Basic Average Shares |
|
228.52
+1.01%
|
226.23
+48.23%
|
152.62
+80.46%
|
84.57
|
| Diluted Average Shares |
|
228.52
+1.01%
|
226.23
+48.23%
|
152.62
+80.46%
|
84.57
|
| Diluted NI Availto Com Stockholders |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
172.25
-45.37%
|
315.29
+1.08%
|
311.92
+14.49%
|
272.45
|
| Current Assets |
|
167.64
-45.90%
|
309.89
+1.10%
|
306.52
+17.05%
|
261.88
|
| Cash Cash Equivalents And Short Term Investments |
|
136.93
-53.51%
|
294.52
-0.64%
|
296.43
+15.94%
|
255.68
|
| Cash And Cash Equivalents |
|
37.73
-18.11%
|
46.07
+43.49%
|
32.11
-71.32%
|
111.97
|
| Other Short Term Investments |
|
99.20
-60.07%
|
248.44
-6.00%
|
264.32
+83.93%
|
143.71
|
| Receivables |
|
12.23
+129.06%
|
5.34
|
0.00
|
—
|
| Other Receivables |
|
12.23
+129.06%
|
5.34
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
6.20
|
| Restricted Cash |
|
—
|
—
|
—
|
0.00
|
| Other Current Assets |
|
18.48
+84.26%
|
10.03
-0.61%
|
10.09
+62.75%
|
6.20
|
| Total Non Current Assets |
|
4.61
-14.79%
|
5.40
+0.13%
|
5.40
-48.94%
|
10.57
|
| Net PPE |
|
4.20
-18.04%
|
5.12
+7.16%
|
4.78
-51.68%
|
9.89
|
| Gross PPE |
|
4.40
-16.97%
|
5.30
-48.06%
|
10.21
-36.19%
|
16.00
|
| Accumulated Depreciation |
|
-0.21
-13.11%
|
-0.18
+96.63%
|
-5.43
+11.13%
|
-6.11
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
—
|
0.00
-100.00%
|
1.27
-5.78%
|
1.35
|
| Construction In Progress |
|
—
|
—
|
0.00
-100.00%
|
0.08
|
| Other Properties |
|
4.33
-18.44%
|
5.30
-16.83%
|
6.38
-46.89%
|
12.01
|
| Leases |
|
0.08
|
0.00
-100.00%
|
2.56
+0.00%
|
2.56
|
| Other Non Current Assets |
|
0.41
+44.17%
|
0.28
-54.21%
|
0.62
-9.12%
|
0.68
|
| Total Liabilities Net Minority Interest |
|
295.01
+3.22%
|
285.80
+14.71%
|
249.15
-4.31%
|
260.37
|
| Current Liabilities |
|
63.44
+40.94%
|
45.01
-12.77%
|
51.60
+4.81%
|
49.23
|
| Payables And Accrued Expenses |
|
31.30
+108.60%
|
15.00
-43.14%
|
26.39
+25.07%
|
21.10
|
| Payables |
|
5.96
+157.22%
|
2.32
-58.03%
|
5.53
+278.75%
|
1.46
|
| Accounts Payable |
|
5.96
+156.96%
|
2.32
-58.03%
|
5.53
+278.75%
|
1.46
|
| Current Accrued Expenses |
|
25.33
+99.72%
|
12.69
-39.20%
|
20.86
+6.22%
|
19.64
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
11.21
-6.54%
|
11.99
+16.52%
|
10.29
-23.94%
|
13.53
|
| Total Tax Payable |
|
0.01
|
0.00
|
—
|
—
|
| Income Tax Payable |
|
0.01
|
0.00
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.94
-2.39%
|
0.96
-93.56%
|
14.91
+2.19%
|
14.60
|
| Current Debt |
|
—
|
—
|
11.61
+0.00%
|
11.61
|
| Other Current Borrowings |
|
—
|
—
|
11.61
+0.00%
|
11.61
|
| Current Capital Lease Obligation |
|
0.94
-2.39%
|
0.96
-70.90%
|
3.30
+10.69%
|
2.98
|
| Current Deferred Liabilities |
|
19.99
+17.23%
|
17.05
|
0.00
|
—
|
| Current Deferred Revenue |
|
19.99
+17.23%
|
17.05
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
231.57
-3.83%
|
240.79
+21.89%
|
197.55
-6.44%
|
211.14
|
| Long Term Debt And Capital Lease Obligation |
|
201.97
+0.02%
|
201.92
+2.21%
|
197.55
-6.44%
|
211.14
|
| Long Term Debt |
|
198.51
+0.50%
|
197.52
+0.06%
|
197.41
-4.96%
|
207.70
|
| Long Term Capital Lease Obligation |
|
3.46
-21.33%
|
4.40
+2954.17%
|
0.14
-95.82%
|
3.45
|
| Non Current Deferred Liabilities |
|
29.61
-23.83%
|
38.87
|
0.00
|
—
|
| Non Current Deferred Revenue |
|
29.61
-23.83%
|
38.87
|
0.00
|
—
|
| Stockholders Equity |
|
-122.76
-516.25%
|
29.49
-53.02%
|
62.77
+419.74%
|
12.08
|
| Common Stock Equity |
|
-122.76
-516.25%
|
29.49
-53.02%
|
62.77
+419.74%
|
12.08
|
| Capital Stock |
|
0.02
+4.35%
|
0.02
+0.00%
|
0.02
+130.00%
|
0.01
|
| Common Stock |
|
0.02
+4.35%
|
0.02
+0.00%
|
0.02
+130.00%
|
0.01
|
| Share Issued |
|
233.68
+3.12%
|
226.60
+0.53%
|
225.41
+138.72%
|
94.42
|
| Ordinary Shares Number |
|
233.68
+3.12%
|
226.60
+0.53%
|
225.41
+138.72%
|
94.42
|
| Additional Paid In Capital |
|
1,321.30
+1.89%
|
1,296.85
+1.70%
|
1,275.14
+22.04%
|
1,044.86
|
| Retained Earnings |
|
-1,438.94
-13.43%
|
-1,268.57
-4.66%
|
-1,212.04
-17.42%
|
-1,032.22
|
| Gains Losses Not Affecting Retained Earnings |
|
-5.15
-533.05%
|
1.19
+439.71%
|
-0.35
+39.02%
|
-0.57
|
| Other Equity Adjustments |
|
-5.15
-533.05%
|
1.19
+439.71%
|
-0.35
+39.02%
|
-0.57
|
| Total Equity Gross Minority Interest |
|
-122.76
-516.25%
|
29.49
-53.02%
|
62.77
+419.74%
|
12.08
|
| Total Capitalization |
|
75.75
-66.63%
|
227.01
-12.74%
|
260.17
+18.38%
|
219.77
|
| Working Capital |
|
104.21
-60.66%
|
264.88
+3.91%
|
254.92
+19.88%
|
212.65
|
| Invested Capital |
|
75.75
-66.63%
|
227.01
-16.47%
|
271.79
+17.46%
|
231.39
|
| Total Debt |
|
202.91
+0.01%
|
202.88
-4.51%
|
212.46
-5.88%
|
225.74
|
| Net Debt |
|
160.78
+6.16%
|
151.45
-14.39%
|
176.91
+64.82%
|
107.34
|
| Capital Lease Obligations |
|
4.40
-17.93%
|
5.36
+55.51%
|
3.45
-46.40%
|
6.43
|
| Net Tangible Assets |
|
-122.76
-516.25%
|
29.49
-53.02%
|
62.77
+419.74%
|
12.08
|
| Tangible Book Value |
|
-122.76
-516.25%
|
29.49
-53.02%
|
62.77
+419.74%
|
12.08
|
| Interest Payable |
|
0.83
+0.00%
|
0.83
-13.95%
|
0.97
-9.11%
|
1.06
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-171.27
-4838.47%
|
-3.47
+97.82%
|
-159.16
+14.90%
|
-187.03
|
| Cash Flow From Continuing Operating Activities |
|
-171.27
-4838.47%
|
-3.47
+97.82%
|
-159.16
+14.90%
|
-187.03
|
| Net Income From Continuing Operations |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Depreciation Amortization Depletion |
|
1.00
-75.86%
|
4.15
-5.34%
|
4.38
-0.99%
|
4.43
|
| Depreciation |
|
1.00
-75.86%
|
4.15
-5.34%
|
4.38
-0.99%
|
4.43
|
| Depreciation And Amortization |
|
1.00
-75.86%
|
4.15
-5.34%
|
4.38
-0.99%
|
4.43
|
| Other Non Cash Items |
|
8.46
+679.01%
|
1.09
-90.41%
|
11.32
+821.91%
|
1.23
|
| Stock Based Compensation |
|
10.55
-48.81%
|
20.62
-27.70%
|
28.52
-32.98%
|
42.55
|
| Operating Gains Losses |
|
-0.01
-100.62%
|
0.81
+11.02%
|
0.73
|
—
|
| Gain Loss On Investment Securities |
|
-0.01
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.81
+11.02%
|
0.73
|
0.00
|
| Change In Working Capital |
|
-13.63
-134.54%
|
39.46
+365.89%
|
-14.84
-232.83%
|
-4.46
|
| Change In Receivables |
|
-6.89
-29.06%
|
-5.34
|
0.00
|
0.00
|
| Change In Prepaid Assets |
|
-8.45
-13733.87%
|
0.06
+101.59%
|
-3.89
-1414.86%
|
0.30
|
| Change In Payables And Accrued Expense |
|
9.12
+212.20%
|
-8.13
-1.28%
|
-8.03
-229.87%
|
-2.43
|
| Change In Accrued Expense |
|
11.87
+283.31%
|
-6.48
+46.12%
|
-12.02
-1835.43%
|
-0.62
|
| Change In Payable |
|
-2.75
-65.88%
|
-1.66
-141.50%
|
3.99
+320.08%
|
-1.81
|
| Change In Account Payable |
|
-2.75
-65.88%
|
-1.66
-141.50%
|
3.99
+320.08%
|
-1.81
|
| Change In Other Working Capital |
|
-6.33
-111.31%
|
55.92
|
—
|
1.62
|
| Change In Other Current Assets |
|
-0.12
-137.31%
|
0.34
+440.32%
|
0.06
-84.50%
|
0.40
|
| Change In Other Current Liabilities |
|
-0.96
+71.62%
|
-3.39
-13.55%
|
-2.98
-9.59%
|
-2.72
|
| Investing Cash Flow |
|
156.36
+438.74%
|
29.02
+126.15%
|
-110.97
-10621.74%
|
-1.03
|
| Cash Flow From Continuing Investing Activities |
|
156.36
+438.74%
|
29.02
+126.15%
|
-110.97
-10621.74%
|
-1.03
|
| Net PPE Purchase And Sale |
|
-0.08
|
0.00
|
0.00
+100.00%
|
-0.41
|
| Purchase Of PPE |
|
-0.08
|
0.00
|
0.00
+100.00%
|
-0.41
|
| Capital Expenditure |
|
-0.08
|
—
|
—
|
-0.47
|
| Net Investment Purchase And Sale |
|
156.44
+439.01%
|
29.02
+126.15%
|
-110.97
-19716.07%
|
-0.56
|
| Purchase Of Investment |
|
-227.11
+54.10%
|
-494.78
-12.02%
|
-441.67
-85.53%
|
-238.06
|
| Sale Of Investment |
|
383.54
-26.78%
|
523.80
+58.39%
|
330.70
+39.24%
|
237.50
|
| Net Intangibles Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-0.07
|
| Purchase Of Intangibles |
|
—
|
0.00
|
0.00
+100.00%
|
-0.07
|
| Financing Cash Flow |
|
6.42
+155.93%
|
-11.49
-106.04%
|
190.15
+62.40%
|
117.09
|
| Cash Flow From Continuing Financing Activities |
|
6.42
+155.93%
|
-11.49
-106.04%
|
190.15
+62.40%
|
117.09
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-12.58
-8.34%
|
-11.61
-100.02%
|
-5.81
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-12.58
-8.34%
|
-11.61
-100.02%
|
-5.81
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-12.58
-8.34%
|
-11.61
-100.02%
|
-5.81
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-12.58
-8.34%
|
-11.61
-100.02%
|
-5.81
|
| Net Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
201.32
+67.84%
|
119.95
|
| Proceeds From Stock Option Exercised |
|
6.42
+487.83%
|
1.09
+146.17%
|
0.44
-84.95%
|
2.95
|
| Changes In Cash |
|
-8.48
-160.30%
|
14.07
+117.59%
|
-79.97
-12.68%
|
-70.98
|
| Effect Of Exchange Rate Changes |
|
0.14
+238.24%
|
-0.10
-192.73%
|
0.11
+121.28%
|
-0.52
|
| Beginning Cash Position |
|
46.07
+43.49%
|
32.11
-71.32%
|
111.97
-38.97%
|
183.47
|
| End Cash Position |
|
37.73
-18.11%
|
46.07
+43.49%
|
32.11
-71.32%
|
111.97
|
| Free Cash Flow |
|
-171.34
-4840.74%
|
-3.47
+97.82%
|
-159.16
+15.12%
|
-187.51
|
| Interest Paid Supplemental Data |
|
10.00
-5.31%
|
10.56
-14.05%
|
12.29
-3.34%
|
12.71
|
| Amortization Of Securities |
|
-7.28
+44.28%
|
-13.06
-38.22%
|
-9.45
-572.60%
|
-1.41
|
| Change In Interest Payable |
|
0.00
+100.00%
|
-0.14
-39.18%
|
-0.10
-9600.00%
|
-0.00
|
| Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
201.32
+67.84%
|
119.95
|
| Issuance Of Capital Stock |
|
0.00
|
0.00
-100.00%
|
201.32
+67.84%
|
119.95
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-05-18 View
- 10-Q2026-05-15 View
- 8-K2026-04-09 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 8-K2026-03-17 View
- 10-K2026-03-17 View
- 8-K2026-02-23 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 8-K2025-11-05 View
- 10-Q2025-11-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|